Literature DB >> 31154465

Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy.

Antonio B Porcaro1,2, Alessandro Tafuri3,4, Marco Sebben3, Giovanni Novella3, Tania Processali3, Marco Pirozzi3, Nelia Amigoni3, Riccardo Rizzetto3, Aliasger Shakir4, Arianna Mariotto3, Matteo Brunelli5, Maria Angela Cerruto3, Giovanni Enrico Cacciamani4, Filippo Migliorini3, Salvatore Siracusano3, Walter Artibani3.   

Abstract

PURPOSE: To assess associations of prostate volume index (PVI), defined as the ratio of the volume of the central transition zone to the volume of the peripheral zone of the prostate and prostatic chronic inflammation (PCI) as predictors of tumor load by number of positive cores (PC) in patients undergoing baseline random biopsies.
METHODS: Parameters evaluated included age, PSA, total prostate volume, PSA density, digital rectal exam, PVI, and PCI. All patients underwent standard transperineal random biopsies. Tumor load was evaluated as absent (no PC), limited (1-3 PC), and extensive (more than 3 PC). The association of factors with the risk of tumor load was evaluated by the multinomial logistic regression model.
RESULTS: The study evaluated 945 patients. Cancer PC were detected in 477 (507%) cases of whom 207 (43.4%) had limited tumor load and 270 (56.6%) had extensive tumor load. Among other factors, comparing patients with limited tumor load with negative cases, PVI [odds ratio, OR = 0.521, 95% confidence interval (CI) 0.330-0.824; p < 0.005] and PCI (OR = 0.289, 95% CI 0.180-0.466; p < 0.0001) were inversely associated with the PCA risk. Comparing patients with extensive tumor load with negative patients, PVI (OR = 0.579, 95% CI 0.356-0.944; p = 0.028), and PCI (OR = 0.150, 95% CI 0.085-0.265; p < 0.0001), predicted PCA risk. Comparing extensive tumor load with limited tumor load patients, PVI and PCI did not show any association with the tumor load.
CONCLUSIONS: Increased PVI and the presence of PCI decreased the risk of increased tumor load and associated with less aggressive prostate cancer biology in patients at baseline random biopsies.

Entities:  

Keywords:  Prostate biopsy; Prostate cancer; Prostate tumor grade; Prostate volume index; Prostate-specific antigen; Prostatic chronic inflammation; Tumor volume

Year:  2019        PMID: 31154465     DOI: 10.1007/s00345-019-02830-7

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  28 in total

Review 1.  The inflammatory microenvironment and microbiome in prostate cancer development.

Authors:  Karen S Sfanos; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Nat Rev Urol       Date:  2017-10-31       Impact factor: 14.432

2.  NIH consensus definition and classification of prostatitis.

Authors:  J N Krieger; L Nyberg; J C Nickel
Journal:  JAMA       Date:  1999-07-21       Impact factor: 56.272

Review 3.  The role of prostatic inflammation in the development and progression of benign and malignant diseases.

Authors:  Giorgio Gandaglia; Emanuele Zaffuto; Nicola Fossati; Vito Cucchiara; Vincenzo Mirone; Francesco Montorsi; Alberto Briganti
Journal:  Curr Opin Urol       Date:  2017-03       Impact factor: 2.309

4.  Inverse Association of Prostatic Chronic Inflammation among Prostate Cancer Tumor Grade Groups: Retrospective Study of 738 Consecutive Cases Elected to a First Random Biopsy Set.

Authors:  Antonio Benito Porcaro; Alessandro Tafuri; Giovanni Novella; Marco Sebben; Arianna Mariotto; Davide Inverardi; Paolo Corsi; Tania Processali; Marco Pirozzi; Nelia Amigoni; Riccardo Rizzetto; Matteo Brunelli; Matteo Balzarro; Salvatore Siracusano; Walter Artibani
Journal:  Urol Int       Date:  2018-04-19       Impact factor: 2.089

5.  Intraprostatic chronic inflammation is associated with a reduced risk of prostate cancer in patients elected to a first random biopsy set.

Authors:  Antonio B Porcaro; Giovanni Novella; Nicolò de Luyk; Paolo Corsi; Giovanni Cacciamani; Marco Sebben; Alessandro Tafuri; Tania Processali; Mattia Cerasuolo; Maria A Cerruto; Matteo Brunelli; Salvatore Siracusano; Walter Artibani
Journal:  Tumori       Date:  2016-11-09       Impact factor: 2.098

Review 6.  EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.

Authors:  Christian Gratzke; Alexander Bachmann; Aurelien Descazeaud; Marcus J Drake; Stephan Madersbacher; Charalampos Mamoulakis; Matthias Oelke; Kari A O Tikkinen; Stavros Gravas
Journal:  Eur Urol       Date:  2015-01-19       Impact factor: 20.096

7.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Authors:  Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford
Journal:  Eur Urol       Date:  2016-08-25       Impact factor: 20.096

Review 8.  Prevalence of incidental prostate cancer: A systematic review of autopsy studies.

Authors:  Katy J L Bell; Chris Del Mar; Gordon Wright; James Dickinson; Paul Glasziou
Journal:  Int J Cancer       Date:  2015-04-21       Impact factor: 7.396

9.  Pathway-based expression profiling of benign prostatic hyperplasia and prostate cancer delineates an immunophilin molecule associated with cancer progression.

Authors:  Ankur Bhowal; Subhadipa Majumder; Subarna Ghosh; Sanmitra Basu; Debrup Sen; Susanta Roychowdhury; Sanghamitra Sengupta; Urmi Chatterji
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more
  4 in total

1.  New Diagnostic Model for Clinically Significant Prostate Cancer in Biopsy-Naïve Men With PIRADS 3.

Authors:  Chen Huang; Feng Qiu; Di Jin; Xuedong Wei; Zongxin Chen; Ximing Wang; Xiaojun Zhao; Linchuan Guo; Jinxian Pu; Jianquan Hou; Yuhua Huang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

2.  Added Value of Biparametric MRI and TRUS-Guided Systematic Biopsies to Clinical Parameters in Predicting Adverse Pathology in Prostate Cancer.

Authors:  Hailang Liu; Kun Tang; Ding Xia; Xinguang Wang; Wei Zhu; Liang Wang; Weimin Yang; Ejun Peng; Zhiqiang Chen
Journal:  Cancer Manag Res       Date:  2020-08-24       Impact factor: 3.989

3.  Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer.

Authors:  Antonio Benito Porcaro; Sebastian Gallina; Alberto Bianchi; Clara Cerrato; Alessandro Tafuri; Riccardo Rizzetto; Nelia Amigoni; Rossella Orlando; Emanuele Serafin; Alessandra Gozzo; Filippo Migliorini; Stefano Zecchini Antoniolli; Vincenzo Lacola; Vincenzo De Marco; Matteo Brunelli; Maria Angela Cerruto; Salvatore Siracusano; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2021-10-22       Impact factor: 2.370

4.  Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection.

Authors:  Antonio Benito Porcaro; Andrea Panunzio; Alessandro Tafuri; Giovanni Mazzucato; Clara Cerrato; Sebastian Gallina; Alberto Bianchi; Riccardo Rizzetto; Nelia Amigoni; Emanuele Serafin; Francesco Cianflone; Rossella Orlando; Ilaria Gentile; Filippo Migliorini; Stefano Zecchini Antoniolli; Giacomo Di Filippo; Matteo Brunelli; Vincenzo Pagliarulo; Maria Angela Cerruto; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2022-01-19       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.